Back to reports
Wish List 0 Cart
0

Attention Deficit Hyperactivity Disorder (ADHD) Disease – Global Clinical Trials Review, H1 2020

Pages: 804 Published: May 30, 2020 Report Code: GDHC6203CTIDB

Add to Wishlist
Select Item

GlobalData's clinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2020" provides an overview of Attention Deficit Hyperactivity Disorder (ADHD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Key Players

  • Takeda Pharmaceutical Co Ltd

    Eli Lilly and Co

    Johnson & Johnson

    Novartis AG

    QPS Holdings LLC

    Supernus Pharmaceuticals Inc

    Neos Therapeutics Inc

    Purdue Pharma LP

    KemPharm Inc

    Arcturus Therapeutics Ltd

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 15

Top Countries Contributing to Clinical Trials in Middle East and Africa 16

Top Countries Contributing to Clinical Trials in Central and South America 17

Clinical Trials by G7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 18

Clinical Trials by Phase in G7 Countries 20

Clinical Trials in G7 Countries by Trial Status 21

Clinical Trials by E7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 23

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 27

In Progress Trials by Phase 29

Clinical Trials by Trial Status 31

Clinical Trials by End Point Status 32

Subjects Recruited Over a Period of Time 34

Clinical Trials by Sponsor Type 35

Prominent Sponsors 36

Top Companies Participating in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials 38

Prominent Drugs 40

Latest Clinical Trials News on Attention Deficit Hyperactivity Disorder (ADHD) 41

Mar 04, 2020: American BriVision first patient enrolled for phase II part I clinical trial for ABV-1505 in adult attention-Deficit Hyperactivity Disorder (ADHD) 41

Feb 28, 2020: American BriVision provides update on ABV-1505 41

Feb 24, 2020: Akili announces publication of AKL-T01 ADHD pivotal study results in the Lancet Digital Health 41

Clinical Trial Profile Snapshots 43

Appendix 801

Abbreviations 801

Definitions 801

Research Methodology 802

Secondary Research 802

About GlobalData 803

Contact Us 803

Source 804

List of Tables

List of Tables

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region, 2020* 8

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 10

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 11

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020* 12

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020* 14

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries, 2020* 15

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2020* 16

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020* 17

Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2020* 19

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 20

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 22

Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2020* 23

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 24

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 26

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase, 2020* 28

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2020* 30

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 31

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 33

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 34

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020* 35

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 37

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 39

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 40

 

List of Figures

List of Figures

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region (%), 2020* 8

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 9

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 11

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020* 12

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020* 13

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2020* 15

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2020* 16

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020* 17

Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2020* 18

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 20

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 21

Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2020* 23

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 24

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 25

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase (%), 2020* 27

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020* 29

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 31

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 32

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 34

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020* 35

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 36

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 38

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 40

GlobalData Methodology 802

 

Frequently Asked Questions

Buy Now

Add to Basket
Enquire Before Buying
$2500

Can be used by individual purchaser only

Most Popular
$5000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
New
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
$3500 | August 12, 2022
Pharmaceuticals
New
New
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
$3500 | August 12, 2022
Pharmaceuticals
New
New
Clinical Trials – The Importance of Diversity in Clinical Trials
$695 | August 12, 2022